[ad_1]
“We trust the European Medicines Agency and its decisions, and we really do not need to anticipate events, let’s wait for the decision of the European Medicines Agency,” the adviser said at a remote press conference on Monday.
The acquisition decision, he said, could then be made “with all aspects in mind.”
“Then, of course, each state makes an individual decision, taking into account all aspects, whether to buy a vaccine from a manufacturer or not,” said S. Krėpšta.
Photo by Julius Kalinskas / 15min / Simonas Krėpšta
The advisor said that now the focus is on vaccination with those vaccines that have already arrived in Lithuania and those that the EMA intends to evaluate in the near future.
“There is a strategic objective to obtain herd immunity in the summer. This means having enough vaccines, safe and effective, without a doubt <...>. Every effort is currently being made to increase volumes from current vendors (Pfizer, Moderna) and will grow fairly steadily in February.
VIDEO: Presidency: the situation allows to facilitate quarantine, take into account the small business
In February, we will receive almost 60 thousand. additional AstraZeneca vaccines, it will be necessary to accelerate the vaccination rate. And, of course, this is the fourth manufacturer, Johnson & Johnson, which will also be licensed in Europe and will provide an additional supply of vaccines.
This is the main focus at the moment, and there is a clear procedure for additional manufacturers, be it the mentioned Russian manufacturer or all other manufacturers, the safety and reliability of this vaccine is evaluated first by agencies and then by each nation. decide whether to buy it. if not necessary “, – repeats S.Krėpšta.
This is not the question of the day.
“It just came to our knowledge then (“Sputnik V” – 15 min) vaccines, “he added.
When asked about purchasing the Sputnik V vaccine last week, Prime Minister Ingrida Šimonytė replied that Lithuania does not plan to acquire it.
On Twitter, he wrote that Sputnik V was being offered to the world. – another hybrid weapon of Russian President Vladimir Putin for fragmentation and control.
To this statement The Russian Embassy in Lithuania also responded.
Josep Borrell, head of diplomacy for the European Union, who visited Moscow last week, expressed his hope that the COVID-19 vaccine developed in Russia will soon be used throughout the Community of 27 Member States, and that the EMA will confirm its effectiveness. .
The Sputnik V vaccine was initially criticized for its haste and lack of transparent information.
However, a comprehensive study by Russian scientists recently appeared in the British scientific journal Lancet, the results of which are beyond question.
It is reported here that the effectiveness of the Russian vaccine, based on clinical trials, is 91%, and those still infected with COVID-19 are more likely to become ill after vaccination.
More about the study and the Sputnik V vaccine against COVID-19 – here.
Recently, these Russian vaccines Hungary has approved its use.
Lithuania is currently vaccinating its population with COVID-19 vaccines from three companies: Pfizer and BioNTech, Moderna and AstraZeneca.
All of them are registered and used in the European Union.
[ad_2]
